Cellectar Reports Q2 Loss, $34M Cash, and Going Concern Doubt
CLRB sits 18% above its 52-week low of $2.2 on light trading volume (0.2× avg).
Summary
Cellectar reported a Q2 net loss of $6.9 million with $34 million in cash. Going concern doubt remains, and liquidity only funds operations through Q2 2027.
Updates
· GlobeNewswire — Initiated site activation for confirmatory Phase 3 trial; NDA submission planned mid-2027; ASCO data showed 87.5% ORR and 79.2% MRR; dosed first patients in Phase 1b CLR 125 trial.
Key Events · Earnings and Guidance · CLRB
-
Q2 Net Loss of $6.9M
Net loss for the three months ended June 30, 2026 was $6,930,653, compared to $5,447,911 in the prior year period. R&D expenses rose 91% to $4.6 million due to Phase 3 and TNBC study initiations.
-
Cash Position of $34M
Cash and cash equivalents were $33,993,982 as of June 30, 2026, up from $13,196,033 at year-end 2025, reflecting $31.7 million net proceeds from the May 2026 financing.
-
Going Concern Doubt Persists
The company states substantial doubt about its ability to continue as a going concern. Available liquidity of approximately $29 million funds operations only through the second quarter of 2027.
-
Material Weaknesses Unresolved
Material weaknesses in internal control over financial reporting, including control environment, risk assessment, and control activities, continue as of June 30, 2026.
Analysis · CLRB · Life Sciences
Cellectar's Q2 10-Q shows a net loss of $6.9 million and cash of $34 million after the May financing. The company still has substantial doubt about its ability to continue as a going concern, with liquidity only funding operations through Q2 2027. Material weaknesses in internal controls persist. The cash runway is short relative to the Phase 3 trial costs, and the company will need additional capital.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLRB was trading at $2.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.8M. The 52-week trading range was $2.20 to $6.52. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.